Pharmadrug Inc. (LMLLF)
OTCMKTS
· Delayed Price · Currency is USD
0.0064
-0.0009 (-12.33%)
Apr 22, 2025, 4:00 PM EDT
Pharmadrug Revenue
Revenue
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
n/a
Market Cap
776.72K USD
Revenue Chart
* This company reports financials in CAD.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| SS Innovations International | 20.65M |
| Endo Inc. | 1.76B |
| Veradigm | 588.02M |
| Northwest Biotherapeutics | 1.38M |
| Elite Pharmaceuticals | 70.00M |
| Glass House Brands | 200.90M |
| BioStem Technologies | 301.83M |
| American Oncology Network | 1.76B |
Pharmadrug News
- 5 months ago - PharmaDrug Announces Issuance of Debenture Units - Newsfile Corp
- 6 months ago - PharmaDrug Announces Proposed Issuance of Debenture Units - Newsfile Corp
- 6 months ago - PharmaDrug's Sairiyo Therapeutics Announces Successful Completion of Stability Study of PD-001 (Patented Reformulated Cepharanthine) to Support Use in Phase 1 Study for Viral Infectious Diseases - Newsfile Corp
- 7 months ago - PharmaDrug's Sairiyo Therapuetics Announces Initiation of Study Start-Up Activities and Design for Clinical Trial of PD-001 (Patented Reformulated Cepharanthine) for Viral Infectious Diseases - Newsfile Corp
- 8 months ago - PharmaDrug's Sairiyo Therapuetics Provides Strategic Plans to Advance PD-001 (Patented Reformulated Cepharanthine) for Viral Infectious Diseases - Newsfile Corp
- 8 months ago - PharmaDrug's Sairiyo Therapuetics Announces Independent Screening Identifying Cepharanthine's Potential to Bind to Monkeypox (Mpox) Proteins - Newsfile Corp
- 8 months ago - PharmaDrug's Sairiyo Therapuetics Receives Approval to Initiate Phase 1 Clinical Trial of Patented Reformulated Cepharanthine - Newsfile Corp
- 1 year ago - PharmaDrug's Sairiyo Therapeutics Submits Clinical Trial Application for Phase 1 Study of Patented Reformulated Cepharanthine - Newsfile Corp